Palumbo AP, Anderson K. Multiple Myeloma. N Engl J Med 2011;364(11):1046-60. No abstract available

Lonial S et al. Exploring the clinical decisions of US community-based oncologists and hematologists in the management of multiple myeloma and follicular lymphoma. Oncology 2010;24(12 Suppl 5):8-14.

Randomized trial of lenalidomide, bortezomib, dexamethasone vs high-dose treatment with SCT in MM patients up to age 65 (IFM/DFCI2009). NCT01208662

Attal M et al. Maintenance treatment with lenalidomide after transplantation for myeloma: Final analysis of the IFM 2005-02. Proc ASH 2010;Abstract 310.

Attal M et al. Maintenance treatment with lenalidomide after transplantation for myeloma: Analysis of secondary malignancies within the IFM 2005-02 trial. Proc 13^th IMW 2011;Abstract.

McCarthy PL et al. Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104. Proc ASH 2010;Abstract 37.

McCarthy P et al. Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104. Proc 13^th IMW 2011;Abstract.

Quach H et al. Managing multiple myeloma in the elderly: Are we making progress? Expert Rev Hematol 2011;4(3):301-15. Abstract

Temel JS et al. Effect of early palliative care (PC) on quality of life (QOL), aggressive care at the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a phase III randomized trial. Proc ASCO 2010;Abstract 7509.

Bertolotti P et al. Management of side effects of novel therapies for multiple myeloma: Consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board. Clin J Oncol Nurs 2008;12(3 Suppl):9-12. Abstract

Palumbo A et al. A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. Proc ASCO 2009;Abstract 8515.

Moreau P et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12(5):431-40. Abstract

Moreau P et al. A phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma. Proc ASH 2010;Abstract 312.

Morgan GJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial. Lancet 2010;376(9757):1989-99. Abstract

Potrata B et al. Understanding distress and distressing experiences in patients living with multiple myeloma: An exploratory study. Psychooncology 2011;20(2):127-34. Abstract

Molassiotis A et al. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology 2011;20(1):88-97. Abstract